InQuery vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 40)
InQuery logo

InQuery

EmergingHealthcare

General

SF YC W24 AI medical record review for health insurance prior auth and claims; $3.1M from General Catalyst/DRW/YC deploying AI agents that process clinical documentation for coverage decisions competing with Cohere Health.

AI VisibilityBeta
Overall Score
C40
Category Rank
#380 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
41
Perplexity
36
Gemini
38

About

InQuery is a San Francisco-based AI healthcare platform — backed by Y Combinator (W24) with $3.1 million in total funding from Y Combinator, General Catalyst, Amino Capital, and DRW Venture Capital — providing health insurance companies and managed care organizations with AI agents that autonomously review medical records, analyze clinical documentation, and process prior authorization and claims decisions at a speed and scale that human reviewers cannot match. Founded in 2023, InQuery applies large language models trained on clinical documentation to the insurance review workflows that currently require teams of nurses and physician advisors to manually read through hundreds of pages of medical records per case.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

40
Overall Score
93
#380
Category Rank
#1
77
AI Consensus
80
stable
Trend
stable
41
ChatGPT
94
36
Perplexity
89
38
Gemini
94
36
Claude
92
45
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.